VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that preclinical data from its kt-5000AI ATR inhibitor program will be presented in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18 to 20, 2026 at the Barcelona International Convention Centre (CCIB) in Barcelona, Spain.
The poster highlights novel ATR inhibitor compounds designed using Variational AI’s Enki™ generative AI platform to target tumours characterized by the loss of PTEN, a key tumour-suppressor gene. PTEN loss is among the most common tumour-suppressor alterations in primary prostate cancer and is associated with increased replication stress and a heightened reliance on ATR-mediated DNA damage response pathways. This vulnerability provides a compelling therapeutic rationale for ATR inhibition.
Building on this scientific rationale, the program initially explored the potential benefits of concurrent ATR and mTOR inhibition, as reflected in the originally submitted abstract title. Subsequent lead optimization has prioritized the development of brain-penetrant, ATR-selective compounds, while preserving opportunities to further investigate dual ATR/mTOR inhibition.
Presentation Details:
Abstract Number: 164
Title: Dual ATR-mTOR inhibitors for PTEN-deficient prostate cancer
Presentation Format: Poster Presentation
Poster Board: PB-059
Date/Time: Thursday, November 19, 2026 | 09:00 to 17:30 CET
Location: Centre de Convencions Internacional de Barcelona (CCIB), Barcelona, Spain
The poster will present in vitro enzymatic activity against ATR, selectivity against PIKK family enzymes, viability of PTEN-deficient and PTEN-proficient prostate cancer cell lines, in vitro metabolic stability and mouse pharmacokinetic profiling.
As previously reported, optimized compounds from the kt-5000AI program have demonstrated potent and selective ATR inhibition together with improved metabolic stability. The program remains in preclinical development, and lead optimization is ongoing.
“PTEN-deficient prostate cancer is a setting where the rationale for ATR inhibition is strong and the need for better options is clear,” said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “Presenting at ENA gives our team the opportunity to share this work with the translational oncology community in Europe, and it follows closely on the data we are presenting at the Society for Neuro-Oncology Annual Meeting this month.”
About the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
The EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, known as ENA, is organized jointly by the European Organisation for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research. The symposium brings together researchers and clinicians working in molecular and translational cancer therapeutics.
For more information, please visit: https://event.eortc.org/ena2026/
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI). By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For Further Information Contact:
Kim Oishi
CEO
Kim.oishi@rakovinatherapeutics.com
Mark Mitchell
IR@rakovinatherapeutics.com
Notice Regarding Rakovina Therapeutics Forward-Looking Statements:
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.
Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedarplus.ca.



© 2026 Canjex Publishing Ltd. All rights reserved.